MedPath

Bariatric Surgery for the Reduction of CArdioVascular Events Randomized Controlled Trial

Not Applicable
Recruiting
Conditions
Cardiovascular Complication
Bariatric Surgery Candidate
Registration Number
NCT05531474
Lead Sponsor
Population Health Research Institute
Brief Summary

The primary objective of this study is to evaluate if, in patients with severe obesity (body mass index (BMI) ≥30 kg/m2) and high-risk cardiovascular disease (CVD), bariatric surgery compared to medical weight management (MWM) safely reduces the risk of major cardiovascular events. The cost-effectiveness of bariatric surgery will also be examined. Separate sub-studies will be performed to examine the relationship between bariatric surgery and mental health, cardiac structure and function, genomics, proteomics and metabolomics.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria
  1. Body mass index ≥30 kg/m2; OR BMI ≥30 kg/m2 to 34.9 kg/m2 and have type 2 diabetes or are >55 years of age

  2. Age ≥18 years

  3. High-risk CVD, defined as the presence of any one of the following:

    1. High-risk coronary artery disease (CAD) (i.e., history of MI, percutaneous coronary intervention, coronary artery bypass grafting, or stenoses ≥ 50% in 2 or more major coronary arteries)
    2. Left ventricular ejection fraction (LVEF) < 40%
    3. Heart failure with preserved ejection fraction (LVEF > 40%) and either HF hospitalization in the last 2-years or N-terminal pro b-type natriuretic peptide (NT-proBNP) > 300 pg/ml or BNP > 100 pg/ml in the past 12 months
    4. Documented atrial fibrillation (AF) with CHA2DS2-VASc ≥2 stroke risk score
    5. History of any stroke
    6. Documented peripheral arterial disease (PAD) (i.e., peripheral revascularization of the iliac, infra-inguinal or carotid arteries; limb or foot amputation for arterial vascular disease; or ≥50% carotid or peripheral artery stenosis)
Exclusion Criteria
  1. Hospital admission for HF, myocardial infarction, stroke or coronary revascularization within 30 days of randomization
  2. Percutaneous coronary intervention with a drug eluting stent within 90 days of randomization.
  3. Pregnancy
  4. Contraindication to bariatric surgery
  5. Prior bariatric surgery, other than gastric banding
  6. Life expectancy <2 years from non-cardiovascular causes
  7. Inability to provide informed consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Cardiovascular OutcomesThrough study completion, expected average of 6 years

Composite of cardiovascular mortality, myocardial infarction (MI), stroke, and hospitalization for heart failure (HF).

Secondary Outcome Measures
NameTimeMethod
All-cause mortalityThrough study completion, expected average of 6 years
Myocardial infarctionThrough study completion, expected average of 6 years
Cardiovascular mortalityThrough study completion, expected average of 6 years
StrokeThrough study completion, expected average of 6 years
New onset atrial fibrillation as assessed by ECG or heart rhythm monitoringThrough study completion, expected average of 6 years
Cost effectiveness analysis, measured in quality adjusted life yearsThrough study completion, expected average of 6 years

Economic evaluation to compare the costs and health outcomes associated with bariatric surgery and medical weight management

New onset or remission of type 2 diabetes as per Diabetes Canada / American Diabetes Association GuidelinesThrough study completion, expected average of 6 years
Hospitalization for heart failureThrough study completion, expected average of 6 years

Trial Locations

Locations (1)

Hamilton Health Sciences

🇨🇦

Hamilton, Ontario, Canada

Hamilton Health Sciences
🇨🇦Hamilton, Ontario, Canada
Jorge Wong, MD
Contact
905-527-4322
jorge.wong@phri.ca

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.